The 2011 Cancer Diagnostics Market: New Product Development Opportunities, Market Penetration Strategies, Entry Barriers and Risks

16 Feb 2011 • by Natalie Aster

New York - The report “The 2011 Cancer Diagnostics Market: New Product Development Opportunities, Market Penetration Strategies, Entry Barriers and Risks” by Venture Planning Group identifies major opportunities emerging in the cancer diagnostics market during the next ten years; proposes “ideal” product models with tentative prices and operating characteristics; and suggests alternative business expansion strategies for suppliers.

Report Details:

The 2011 Cancer Diagnostics Market: New Product Development Opportunities, Market Penetration Strategies, Entry Barriers and Risks

Published: October 2010
Pages: 15
Price: US$ 850.00

Report Sample Abstract

Matritech's serum based assay reacts with PC-1. Matritech was granted an exclusive worldwide license to prostate cancer-specific nuclear matrix proteins, including PC-1 developed by Johns Hopkins. The specificity of this antibody for cancerous nuclei, as well as its potential ability to identify pre-cancerous conditions on tissue biopsy, may offer an advantage over existing prostate cancer diagnostic products. The company researcher found six nuclear matrix proteins which differ in healthy and cancerous colon cells. When these six proteins are present in the nuclear matrix, it is highly likely that the cell is cancerous. Matrix proteins appear to initiate the process by which genes are activated. In cancer cells, the proteins may physically stabilize DNA and trigger cancer.

Researchers at Columbia-Presbyterian Medical Center (New York, NY) have developed PCR-based amplification/hybridization assay to detect PSA mRNA. The test is sensitive to detect one cancer cell in a million blood cells. Researchers at the College of Physicians and Surgeons of Columbia University (New York, NY) have detected the PTI-1 gene in samples of The BRCA syndrome is typified by mutations of BRCA1 gene which codes for a protein expressed in different tissues.

Roche Elecsys Series

The Elecsys 1010 immunoassay system is designed to process small volumes, while the Elecsys 2010 is designed for larger laboratories. For greater testing capacity, two Elecsys analyzers with sample rack modules can be linked with a conveyor system and an LSM. After the bar codes on the sample containers are read, the samples are automatically directed to an analyzer by the LSM, which controls the rational distribution of samples to the analyzers, and checks the analyzer systems and components. The test menu includes third generation TSH, Free T4, Free T3, T4, T3, TUptake (18 minute incubation time) and STAT (9 minute incubation time) Troponin T, CKMB and HCG. By the end of 1997, the company expects to add LH, FSH, Estradiol, Prolactin, Testosterone, Progesterone, CA-125, CA 19-9, CA 15-3, free PSA, Cyfra, NSE, CA 72-4, folic acid, B12 and ferritin. The Elecsys uses electro chemiluminescence detection and streptavidin-coated paramagnetic microparticles. The Elecsys 1010 is a stand-alone, sequential batch analyzer with STAT capability. It offers six on-board reagents, 66-sample capacity, and throughput of 45 tests per hour. The Elecsys 2010 is a random access analyzer. It holds 15 on-board reagents and offers nearly twice the throughput of the Elecsys 1010.

More information can be found in the report “The 2011 Cancer Diagnostics Market: New Product Development Opportunities, Market Penetration Strategies, Entry Barriers and Risks” by Venture Planning Group .

To order the report or ask for sample pages contact ps@marketpublishers.com

Contacts

MarketPublishers, Ltd.
Mrs. Alla Martin
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
www.marketpublishers.com